Search the Newsreel

Earnings call transcript: RxSight beats Q2 2026 estimates but withdraws guidance

RxSight reported better-than-expected Q2 2026 earnings and revenue, but its stock fell after the company withdrew its full-year guidance due to ongoing pressure in its core business. The ophthalmology company's adjusted EPS beat estimates by $0.25, and revenue topped forecasts, partly aided by a …

RxSight (RXST) Stock Falls on Q2 2026 Earnings

RxSight Inc (NASDAQ:RXST) is scheduled to release its Q2 2026 earnings on August 7, 2026, with revenue expected at $32.55 million and earnings at $-0.32 per share. GuruFocus estimates a significant upside of 518.60% for RXST based on its GF Value of $38.91, despite …

Keysight Technologies Inc. stock underperforms Wednesday when compared to competitors

Keysight Technologies Inc. (KEYS) stock fell by 1.53% on Wednesday, closing at $336.02. This decline occurred despite a mixed trading session where the Dow Jones Industrial Average rose, while the S&P 500 Index decreased. The stock's underperformance ended a four-day winning streak for the …

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences reported strong second-quarter 2026 financial results, with total revenue increasing by 20% year-over-year to $23.4 million, driven by significant growth in Interventional Dry Eye revenue (704% increase). The company raised its full-year 2026 revenue guidance to $88 million to $92 million and …

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RxSight, Inc. reported its financial results for the second quarter of 2026, with total revenue reaching $33.7 million, including $6.5 million from its collaboration with Alcon. The company also announced key strategic developments, such as the appointment of Aziz Mottiwala as CEO and a …

RxSight, Inc. (RXST) Tops Q2 EPS by 25c

RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q2, with earnings per share of ($0.11), significantly surpassing analyst estimates of ($0.36) by $0.25. The company's revenue also exceeded expectations, coming in at $33.74 million against a consensus estimate of $32.21 million.

Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com

Aetna Inc. has updated its Glaucoma Surgery Policy for commercial plans to recognize Sight Sciences' OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma. This coverage, retroactive to July 14, 2026, applies to approximately 25 million Aetna commercial …

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

Sight Sciences announced that Aetna, Inc. has updated its Glaucoma Surgery Policy to recognize the OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma, given specific clinical criteria are met. This decision expands coverage for implant-free, minimally invasive …

Sight Sciences (NASDAQ: SGHT) lifts 2026 outlook after 20% Q2 growth

$100 Invested In Keysight Techs 5 Years Ago Would Be Worth This Much Today

This article calculates the return on a $100 investment in Keysight Technologies (NYSE: KEYS) made five years ago. It shows that such an investment would now be worth $203.20, reflecting an average annual return of 15.42% and outperforming the market by 3.69% annually. The …

Insight Enterprises Earnings: What To Look For From NSIT

Insight Enterprises (NASDAQ: NSIT) is set to announce its earnings results this Thursday. The company exceeded analysts' revenue expectations last quarter, reporting $2.13 billion, up 1.2% year-on-year, and also beat EPS estimates. For the upcoming quarter, the market anticipates a 3.8% year-on-year revenue growth, …

Earnings Preview: IMDX to Report Financial Results Post-market on August 10

This article announces that IMDX is scheduled to report its financial results after market close on August 10. The report will provide key insights into the company's performance, which investors and analysts will be watching closely.

Insight Enterprises earnings up next: Can AI push justify valuation? By Investing.com

Insight Enterprises is scheduled to report its second-quarter earnings, with analysts expecting significant growth in EPS and revenue. The company's stock is trading near a 52-week high, raising questions about whether its recent AI-focused initiatives and strong IT services sector tailwinds can sustain its …

FDA Clears Sight Sciences’ OMNI Ultra Surgical System

Sight Sciences has received FDA 510(k) clearance for its OMNI Ultra surgical system, designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. This implant-free MIGS device is the first to perform circumferential canaloplasty in a single pass and features TruSync Plus …

Keysight delivers new high-performance 4x100GE network cybersecurity test platform

Keysight Technologies has launched the APS-ONE-400, a new modular 4x100GE network cybersecurity test platform. This system enhances performance for Layer 4-7 traffic, encrypted traffic, and Elephant Flow traffic within a single rack unit. It is designed to help network equipment manufacturers, service providers, and …

Insight Enterprises to present at Canaccord Genuity Annual Growth Conference

Insight Enterprises (NASDAQ: NSIT) is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 11:30 a.m. ET. CEO Jack Azagury and CFO James Morgado are expected to participate. This news brief was generated by Public Technologies using …

RxSight (NASDAQ: RXST) reports $33.7M Q2 revenue and $60M Alcon collaboration

Rxsight earnings beat by $0.25, revenue topped estimates

RxSight (NASDAQ:RXST) Releases Earnings Results, Beats Estimates By $0.22 EPS

Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences’ Record Dry Eye Revenue Jumps 704% to $2.7M

Insight Enterprises stock hits 52-week high at 136.65 USD By Investing.com

Insight Enterprises Inc. (NSIT) stock has reached a new 52-week high of $136.65, demonstrating a 61% return over the past six months and nearly 62% year-to-date gain. Recent developments include strong Q1 2026 earnings, an amended credit agreement, approval of changes to voting standards, …

iMDx to Release Second Quarter Results on August 10, 2026

Insight Molecular Diagnostics Inc. (iMDx) announced it will release its second-quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar for discussion. Additionally, iMDx's CEO and CFO will participate in the 11th Annual Needham Virtual MedTech & …

RxSight (RXST): Millennium entities, Israel Englander report 7.3% ownership stake

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a 7.3% ownership stake in RxSight, Inc. (RXST), totaling 3,030,287 shares as of June 30, 2026. The filing indicates that all beneficially owned shares have shared voting and dispositive power, with …

FDA clears Sight Sciences’ OMNI Ultra glaucoma device By Investing.com

Sight Sciences Inc. (NASDAQ:SGHT) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its OMNI Ultra Surgical System. This device is designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma through canaloplasty followed by trabeculotomy. The …

Keysight Technologies Inc (KEYS) Stock Up 6.0% but GF Value Says Overvalued -- GF Score: 82/100

Keysight Technologies Inc (KEYS) saw its stock rise by 6.0% to $341.24, yet GuruFocus's GF Value™ indicates the stock is 67.9% overvalued compared to its intrinsic value of $203.26. Despite a strong GF Score™ of 82/100, driven by high profitability and growth, the low …

Sight Sciences' FDA-cleared glaucoma system leaves no implant behind

Sight Sciences (Nasdaq: SGHT) has received FDA 510(k) clearance for its OMNI Ultra Surgical System, designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. This system is notable as the first FDA-cleared MIGS device for single-pass circumferential canaloplasty and is implant-free, …

Insight CEO and CFO to Participate in Aug. 11 Conference

Insight Enterprises (Nasdaq: NSIT) announced that its CEO, Jack Azagury, and CFO, James Morgado, are scheduled to participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 11:30 AM ET. A live webcast of their presentation will be available on …

Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ:RXST) securities. The investigation focuses on whether RxSight and its officers engaged in corporate wrongdoing. Investors who purchased RxSight securities before November 7, 2024, and continue to hold …

Insight Molecular Diagnostics updates financial calendar ahead of quarterly results webinar

Insight Molecular Diagnostics announced updates to its financial calendar, scheduling its Q2 2026 results webinar for August 10, 2026, at 5 p.m. ET. Additionally, management will participate in the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This news brief was …

Navan Delivers Real-Time Financial Control for Insight Enterprises

Navan unifies Solutions Integrator's travel and expense infrastructure globally across 26 countries PALO ALTO, Calif., August 04, 2026--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered travel and expense management platform, today announced it has been selected by Insight Enterprises (NASDAQ: NSIT), a leading Solutions Integrator …

Insight Aims to Reallocate 20,000+ Hours Through Automation

Navan, an AI-powered travel and expense management platform, has partnered with Insight Enterprises to unify its travel and expense infrastructure across 26 countries. This collaboration is expected to lead to significant efficiencies, including an estimated 8% reduction in travel spend and the reallocation of …

Keysight Technologies (NYSE: KEYS) officer surrenders 32 shares for taxes

Keysight Technologies VP and Controller Lisa M. Poole surrendered 32 shares of common stock on August 1, 2026, to satisfy tax liability related to the release of restricted shares. The transaction, valued at $319.08 per share, was a tax-withholding disposition under Rule 16b-3, not …

Keysight (KEYS): Buy, Sell, or Hold Post Q1 Earnings?

Sight Sciences Announces FDA 510(k) Clearance of OMNI Ultra Surgical System for Primary Open-Angle Glaucoma

Sight Sciences has received FDA 510(k) clearance for its OMNI Ultra surgical system, designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. This implant-free MIGS device is the first to perform circumferential canaloplasty in a single pass and features TruSync Plus …